Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1998-12-1
pubmed:abstractText
Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the study of VEGF in relation to the menstrual cycle could help further the understanding of this issue of surgical intervention. Fourteen premenopausal women were recruited, along with three post-menopausal women, a woman on an oral contraceptive pill and a single male subject. Between eight and 11 samples were taken per person, over one menstrual cycle (over 1 month in the five controls) and analysed for sex hormones and VEGF165. Serum VEGF was significantly lower in the luteal phase and showed a significant negative correlation with progesterone in all 14 premenopausal women. No inter-sample variations of VEGF were noted in the controls. Serum from both phases of the cycle from one subject was added to MCF-7 breast cancer cells; VEGF expression in the supernatant was lower in the cells to which the luteal phase serum was added. The lowering of a potent angiogenic cytokine in the luteal phase suggests a possible decreased potential for micrometastasis establishment in that phase. This fall in VEGF may be an effect of progesterone and should be the focus of future studies.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-1592003, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-1729274, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-1791185, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-1863022, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-2478587, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-2571865, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-5043412, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7535799, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7553632, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7556649, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7584949, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7592779, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7596435, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7683111, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7683699, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7759509, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7814392, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-7911875, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8107827, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8119973, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8481475, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8521408, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8534867, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8557680, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8602241, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-8631034, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-9020488, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-9332682, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-9607588, http://linkedlifedata.com/resource/pubmed/commentcorrection/9820181-9816236
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1203-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:9820181-Analysis of Variance, pubmed-meshheading:9820181-Breast Neoplasms, pubmed-meshheading:9820181-Breast Neoplasms, Male, pubmed-meshheading:9820181-Endothelial Growth Factors, pubmed-meshheading:9820181-Estradiol, pubmed-meshheading:9820181-Female, pubmed-meshheading:9820181-Humans, pubmed-meshheading:9820181-Lymphokines, pubmed-meshheading:9820181-Male, pubmed-meshheading:9820181-Menstrual Cycle, pubmed-meshheading:9820181-Middle Aged, pubmed-meshheading:9820181-Premenopause, pubmed-meshheading:9820181-Progesterone, pubmed-meshheading:9820181-Time Factors, pubmed-meshheading:9820181-Treatment Outcome, pubmed-meshheading:9820181-Tumor Cells, Cultured, pubmed-meshheading:9820181-Vascular Endothelial Growth Factor A, pubmed-meshheading:9820181-Vascular Endothelial Growth Factors
pubmed:year
1998
pubmed:articleTitle
Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery?
pubmed:affiliation
Academic Surgical Unit, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, UK.
pubmed:publicationType
Journal Article, Clinical Trial